Teva Pharmaceuticals in the news

Teva Pharmaceutical, founded in 1901 in Israel, is the world's largest generic drug manufacturer with a portfolio of over 3,500 medicines.

Teva Pharmaceuticals presented positive new efficacy and safety data for its investigational drug, ecopipam, for treating pediatric Tourette syndrome at a medical congress.

Teva Pharmaceutical and Samsung Bioepis have broadened their existing collaboration to develop and commercialize up to six additional biosimilar products.

The Royal College of Nursing ended its partnership with Teva UK due to concerns over the pharmaceutical company's alleged links to the Israeli military, prompted by campaigning groups.

The federal government asked the full D.C. Circuit to reconsider a ruling that allowed Teva to challenge Medicare's drug price negotiation rules.

Britain's largest nursing union, RCN, ended its sponsorship deal with Teva UK following pro-Palestinian pressure and concerns over Teva's legal issues, while Teva's innovative drug sales and stock value are significantly increasing.

The Royal College of Nursing cut ties with Teva Pharmaceutical Industries, citing the company's links to the Israel Defense Forces and a record of corporate misconduct, leading to the cancellation of Teva's sponsorship for an upcoming migraine conference.

Teva Pharmaceuticals reported positive Phase IIa trial results for its TEV '408 antibody, showing effectiveness in preventing intestinal damage in celiac disease.

Samsung Bioepis and Teva Pharmaceutical Industries expanded their partnership to develop and commercialize two new biosimilar candidates, SB41 and SB44, for the US, European, and Canadian markets.

Teva and Samsung Bioepis expanded their biosimilar collaboration to include up to six new biosimilar candidates, with Teva managing global commercialization and Samsung Bioepis leading development and manufacturing.

Teva Pharmaceutical and Samsung Bioepis deepened their partnership to develop and commercialize up to six new biosimilars, with Samsung Bioepis handling development and Teva managing commercialization worldwide.

The UK's Royal College of Nursing ended its partnership with Teva UK due to the Israeli pharmaceuticals firm's alleged ties to the Israel Defense Forces and a record of corporate misconduct, including significant fines for bribery and price-fixing.

Teva Pharmaceuticals disclosed positive clinical trial results for its drug ecopipam for movement disorders, but its stock is significantly overvalued and shows insider selling.

The Royal College of Nursing (RCN) cut ties with Teva Pharmaceuticals due to the Israeli drugmaker's links to the Israeli military and a history of corruption scandals, prompting pro-Palestine groups to hail the decision as a success.

Samsung Bioepis and Teva Pharmaceutical Industries formed a global agreement for developing and commercializing up to six biosimilar candidates, including SB41 and SB44.

Teva Pharmaceutical (NYSE:TEVA) is nearing a breakout with strong technical ratings and a bull flag setup, indicating a potential continuation of its uptrend.

TD Cowen initiated coverage on Teva Pharmaceutical Industries (NYSE:TEVA) with a "buy" rating and a $55.00 price target, while other analysts maintain a "Moderate Buy" consensus.

Teva Pharmaceuticals transformed into a high-margin, innovation-led biopharmaceutical company by pivoting from generics to branded medicines, reducing debt, and resolving legal issues.

A report on October 1, 2026, details market movements for futures, bonds, oil, gold, and crypto, and lists Wall Street analyst upgrades, downgrades, and initiations, including a 'Buy' rating for Teva Pharmaceuticals.

TD Cowen initiated coverage on Teva Pharmaceutical Industries Ltd. with a buy rating and a $55 price target, citing its strong product pipeline and recent positive developments.